Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of incretin based agents for the treatment of type 2 diabetes, have intermediate efficacy regarding glucose control with a satisfactory tolerability profile5, 6, 7. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.